Rich Heyman's Metacrine tacks on another $65M to tackle a superior NASH drug
Just six months after unwrapping its B round to push a NASH drug through the clinic, San Diego’s Metacrine is ramping up efforts towards that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
